AT 02 - Alethio Therapeutics
Alternative Names: AT-02 - Alethio TherapeuticsLatest Information Update: 09 Jan 2026
At a glance
- Originator Alethio Therapeutics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer